RLY-4008 Shows DCR of 100% in FGFR+ Cholangiocarcinoma
September 11th 2022A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.
Read More
Neoadjuvant Nivolumab/Ipilimumab Shows Unprecedented Pathologic Responses in dMMR Colon Cancer
September 11th 2022At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.
Read More
Tailoring Nivolumab and Ipilimumab Therapy Leads to Better Responses in RCC
September 11th 2022A more tailored approach to treatment with PD-1 and CTLA-4 immune checkpoint blockade led to improved responses for patients with advanced renal cell carcinoma in both the first- and second-line settings, according to final results from the phase 2 TITAN-RCC trial.
Read More
Trastuzumab Deruxtecan Preserves QOL in HER2-Low Breast Cancer
September 11th 2022Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.
Read More
First-line Olaparib Triplet Improves Outcomes in mCRPC
September 11th 2022Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.
Read More
Additional Follow-up for CLEAR Trial Shows Maintained Lenvatinib/Pembrolizumab Benefit in RCC
September 11th 2022Even after additional follow-up, the CLEAR trial showed a benefit for the combination of lenvatinib and pembrolizumab over sunitinib in patients with advanced clear cell renal cell carcinoma.
Read More
Novel ULK Inhibitor Considered Safe for Solid Tumors Harboring RAS or RAF Mutations
September 11th 2022DCC-3116 demonstrated safety and tolerability across various dose levels in patients with solid tumors harboring a RAS or RAF mutation, according to findings from a phase 1/2 trial presented at the 2022 ESMO Congress.
Read More
Biomarkers May Help Predict Responses to Avelumab in Urothelial Carcinoma
September 11th 2022Multiple blood-based biomarkers suggest potential responses to treatment with maintenance avelumab for patients with advanced or metastatic urothelial carcinoma from the phase 3 JAVELIN Bladder 100 trial, according to an exploratory analysis presented at the European Society for Medical Oncology Congress 2022.
Read More
Enzalutamide/Abiraterone Acetate/Prednisolone Combo in mHSPC Not Recommended
September 11th 2022Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.
Read More
Lenvatinib/Pembrolizumab Benefit Maintained in Advanced Endometrial Cancer
September 11th 2022After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.
Read More
Benefit of Maintenance Rucaparib in Ovarian Cancer Seen Across Subgroups
September 11th 2022Maintenance rucaparib (Rubraca) induced a progression-free survival (PFS) improvement in patients with newly diagnosed ovarian cancer compared with placebo, which was also seen across all prespecified subgroups.
Read More
No Significant Improvement of DFS Seen in High-Risk RCC With Adjuvant Nivolumab/Ipilimumab
September 11th 2022Adjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high risk for relapse after nephrectomy failed to significantly improve disease-free survival vs placebo in part A of the phase 3 CheckMate 914 trial.
Read More
Promising Results Demonstrated With Blood Tests for Early Cancer Detection
September 11th 2022Positive signals from a blood-based multi-cancer early detection test led to cancer diagnoses after the test indicated potential cancers in 1.4% of individuals from an otherwise healthy cohort of participants in the the prospective PATHFINDER study.
Read More
Xevinapant Plus CRT in Locally Advanced HNSCC Shows Continued Benefit
September 11th 2022Improvement in overall survival for patients with locally advanced head and neck squamous cell carcinoma was demonstrated with xevinapant plus standard chemoradiotherapy vs matched placebo at the 5-year mark.
Read More
Updated Results Support Efficacy of Trastuzumab Deruxtecan in Metastatic Gastric/GEJ Cancer
September 11th 2022New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Read More
Frontline Tislelizumab Shows Non-Inferior OS vs Sorafenib in Unresectable HCC
September 11th 2022At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.
Read More
KEYNOTE-365 2-Year Update Shows Benefit of Pembrolizumab Plus Abiraterone in mCRPC
September 11th 2022An updated analysis of the KEYNOTE-365 study of pembrolizumab plus abiraterone showed that patients with chemotherapy-naive metastatic castration-resistant prostate cancer had prostate-specific antigen responses.
Read More
Sacituzumab Govitecan Shows Strong ORR, PFS Benefit in HER2-Low/IHC0 Metastatic Breast Cancer
September 10th 2022The antibody-drug conjugate sacituzumab govitecan demonstrated superior overall response rate and progression-free survival in patients with breast cancer with limited options due to lack of high HER2 expression.
Read More
Lasofoxifene Improves Certain Responses in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
September 10th 2022While lasfoxifene alone did not meet the primary end points that researchers set out for it, they did find that it improves responses in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Read More